MRTX1133 is an investigational drug that targets the G12D mutation in KRAS dependent cancers.[1][2] It is currently in a phase 1/2 clinical trial for the treatment of solid tumors.[3] MRTX1133 is considered to be harmful from direct skin or eye exposure other than transient irritation. It may cause irritation of the respiratory system if inhaled.[4]

See also

References

  1. ^ "MRTX 1133". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD (November 2023). "Next batter up! Targeting cancers with KRAS-G12D mutations". Trends in Cancer. 9 (11): 955–967. doi:10.1016/j.trecan.2023.07.010. PMID 37591766.
  3. ^ Clinical trial number NCT05737706 for "Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation" at ClinicalTrials.gov
  4. ^ "MRTX1133 Safety Data Sheet". TargetMol. Retrieved 11 September 2024.
Allikas: http://en.wikipedia.org/wiki/MRTX1133
No tags for this post.